Adverse Drug Reactions of Tyrosine Kinase Inhibitors in the Treatment of Advanced Lung Cancer

Journal Title: International Journal of Medical Research Professionals - Year 2018, Vol 4, Issue 5

Abstract

Introduction: Erlotinib and gefitinib are the most commonly used epidermal growth factor receptor‑tyrosine kinase inhibitors (EGFR‑TKIs) in the treatment of EGFR mutant nonsmall cell lung cancer (NSCLC). Both erlotinib and gefitinib have shown equal efficacy in terms of response rates and overall survival. Hence, their toxicity profile becomes the most important determining factor in choosing these agents when treating EGFR mutant NSCLC. In this study, we compared the toxicity profile of erlotinib and gefitinib among an Indian subset of lung cancer patients. Materials and Methods: In this prospective nonrandomized study, 85 patients came at Acharya Tulsi Regional Cancer Treatment & Research Institute with NSCLC were tested for EGFR mutation status, and EGFR mutant patients were started on either erlotinib or gefitinib. They were periodically monitored for drug toxicities. Results: Out of the 85 patients tested, 34 patients were positive for EGFR mutation. Eleven of them were started on erlotinib and 23 were started on gefitinib. The most common side effect of TKIs was skin rash. Nine out of the 11 patients started on erlotinib and 7 of the 23 patients started on gefitinib had skin rash. Grade 3 and 4 skin rash was significantly more among patients treated with erlotinib which resulted in treatment delays. Other side effects of TKIs such as diarrhea and deranged liver functions were similar among the both subsets of patients. Conclusion: Skin toxicity is the major and serious side effect with erlotinib among Indian patients with EGFR mutant lung cancer. This resulted in significant treatment delay, which might adversely affect the overall survival of patients. Gefitinib was better tolerated and had a safer toxicity profile compared to erlotinib in Indian patients.

Authors and Affiliations

Pankaj Tantia, Ritika Agarwal, Jitendra Acharya

Keywords

Related Articles

Assessment of Knowledge and Awareness of Ocular Allergy Among Undergraduate Students, University of Tabuk, Tabuk City, Saudi Arabia

Background: Proper knowledge and awareness of university students about ocular allergy may help in decreasing the illness duration or even prevent it. Objectives: To assess the knowledge and awareness among University of...

Risk factors and Outcome of Neonatal Admission to Neonatal Intensive Care Unit in Governmental and Private Hospitals, Al-Madinah Al-Monawarah 2015

Introduction: Various risk factors had been established to be associated with neonatal admission to the intensive care units. These risk factors are laid down in three key groups including maternal factors, fetal and del...

Assessment of Microbiological Profile of Bile in Cholecystectomy Patients: A Microbiological Study

Background: Calculus disease of biliary is one of the most common disorders affecting the gastrointestinal tract constituting a major cause of morbidity. Antimicrobial therapy recommendations state that antibiotics shoul...

Assessment of Prevalence of Iron Deficiency Anemia among Patients Reporting to Medicine OPD: An Observational Study

Background: The World Health Organization defines anemia as blood hemoglobin values of less than 7.7 mmol/l (13 g/dl) in men and 7.4 mmol/l (12 g/dl) in women. Typically, the evaluation of the cause of anemia includes a...

To Study Clinical, Hematological and Neuroimaging Profile in Patients of Infantile Tremor Syndrome in a Rural Based Tertiary Care Centre

Background: Vitamin B12 or cobalamin deficiency is a rare and treatable cause of failure to thrive and delayed development in infants. It is especially more common in infants of vegan mothers. There is a report that ever...

Download PDF file
  • EP ID EP537146
  • DOI 10.21276/ijmrp.2018.4.5.064
  • Views 90
  • Downloads 0

How To Cite

Pankaj Tantia, Ritika Agarwal, Jitendra Acharya (2018). Adverse Drug Reactions of Tyrosine Kinase Inhibitors in the Treatment of Advanced Lung Cancer. International Journal of Medical Research Professionals, 4(5), 283-285. https://europub.co.uk/articles/-A-537146